Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction
Brought to you by

Follow-on nets $18.7mm for Venaxis

Executive Summary

Venaxis Inc. (developer of the CE-Marked APPY1 test to identify patients at low risk for acute appendicitis) netted $18.7mm through the follow-on offering of 8.3mm common shares at $2.40. Some of the proceeds will be used to gain FDA approval of and initially commercialize APPY1, plus EU sales and marketing.
Deal Industry
  • In Vitro Diagnostics
Deal Status
  • Final
Deal Type
  • Financing
    • FOPO

Related Companies

Advertisement
UsernamePublicRestriction

Register